Kyverna Therapeutics Statistics
Total Valuation
KYTX has a market cap or net worth of $100.27 million. The enterprise value is -$135.44 million.
Important Dates
The last earnings date was Tuesday, May 13, 2025, after market close.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
KYTX has 43.22 million shares outstanding. The number of shares has increased by 6,313.09% in one year.
| Current Share Class | 43.22M |
| Shares Outstanding | 43.22M |
| Shares Change (YoY) | +6,313.09% |
| Shares Change (QoQ) | -0.04% |
| Owned by Insiders (%) | 2.26% |
| Owned by Institutions (%) | 40.00% |
| Float | 22.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.45 |
| P/TBV Ratio | 0.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.44, with a Debt / Equity ratio of 0.03.
| Current Ratio | 7.44 |
| Quick Ratio | 7.29 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,306.13 |
Financial Efficiency
Return on equity (ROE) is -49.72% and return on invested capital (ROIC) is -33.31%.
| Return on Equity (ROE) | -49.72% |
| Return on Assets (ROA) | -30.86% |
| Return on Invested Capital (ROIC) | -33.31% |
| Return on Capital Employed (ROCE) | -70.66% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.30M |
| Employee Count | 112 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.43% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -83.43% |
| 50-Day Moving Average | 2.21 |
| 200-Day Moving Average | 4.38 |
| Relative Strength Index (RSI) | 56.87 |
| Average Volume (20 Days) | 211,088 |
Short Selling Information
The latest short interest is 2.14 million, so 4.94% of the outstanding shares have been sold short.
| Short Interest | 2.14M |
| Short Previous Month | 2.65M |
| Short % of Shares Out | 4.94% |
| Short % of Float | 9.63% |
| Short Ratio (days to cover) | 8.61 |
Income Statement
| Revenue | n/a |
| Gross Profit | -112.47M |
| Operating Income | -160.65M |
| Pretax Income | n/a |
| Net Income | -145.42M |
| EBITDA | -159.45M |
| EBIT | -160.65M |
| Earnings Per Share (EPS) | -$3.37 |
Full Income StatementBalance Sheet
The company has $242.65 million in cash and $6.94 million in debt, giving a net cash position of $235.71 million or $5.45 per share.
| Cash & Cash Equivalents | 242.65M |
| Total Debt | 6.94M |
| Net Cash | 235.71M |
| Net Cash Per Share | $5.45 |
| Equity (Book Value) | 224.01M |
| Book Value Per Share | 5.18 |
| Working Capital | 214.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$133.64 million and capital expenditures -$1.66 million, giving a free cash flow of -$135.30 million.
| Operating Cash Flow | -133.64M |
| Capital Expenditures | -1.66M |
| Free Cash Flow | -135.30M |
| FCF Per Share | -$3.13 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |